47 related articles for article (PubMed ID: 38565669)
1. Silent suffering: the impact of sexual health challenges on patient-clinician communication and adherence to adjuvant endocrine therapy among Black women with early-stage breast cancer.
Anderson JN; Paladino AJ; Blue R; Dangerfield DT; Eggly S; Martin MY; Schwartzberg LS; Vidal GA; Graetz I
J Cancer Surviv; 2023 Dec; ():. PubMed ID: 38114711
[TBL] [Abstract][Full Text] [Related]
2. Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer.
Lee KT; Jacobs L; Walsh EM; Stearns V; Segal JB
Breast Cancer Res Treat; 2020 Dec; 184(3):965-975. PubMed ID: 32914353
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
Lambert LK; Balneaves LG; Howard AF; Gotay CC
Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
[TBL] [Abstract][Full Text] [Related]
4. Systematic adaptation of the adherence improving self-management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach.
Janssen AM; Dam J; Prins J; Buffart LM; de Bruin M
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13721. PubMed ID: 36263723
[TBL] [Abstract][Full Text] [Related]
5. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
[TBL] [Abstract][Full Text] [Related]
6. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
[TBL] [Abstract][Full Text] [Related]
7. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
[TBL] [Abstract][Full Text] [Related]
8. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
[TBL] [Abstract][Full Text] [Related]
9. Women with breast cancer's perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative study.
Gagné M; Lauzier S; Lemay M; Loiselle CG; Provencher L; Simard C; Guillaumie L
Support Care Cancer; 2022 Jun; 30(6):4759-4768. PubMed ID: 35133477
[TBL] [Abstract][Full Text] [Related]
10. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors.
Bright EE; Finkelstein LB; Nealis MS; Genung SR; Wrigley J; Gu HCJ; Schmiege SJ; Arch JJ
J Clin Oncol; 2023 Oct; 41(28):4548-4561. PubMed ID: 37531593
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gradishar WJ; Moran MS; Abraham J; Aft R; Agnese D; Allison KH; Anderson B; Burstein HJ; Chew H; Dang C; Elias AD; Giordano SH; Goetz MP; Goldstein LJ; Hurvitz SA; Isakoff SJ; Jankowitz RC; Javid SH; Krishnamurthy J; Leitch M; Lyons J; Mortimer J; Patel SA; Pierce LJ; Rosenberger LH; Rugo HS; Sitapati A; Smith KL; Smith ML; Soliman H; Stringer-Reasor EM; Telli ML; Ward JH; Wisinski KB; Young JS; Burns J; Kumar R
J Natl Compr Canc Netw; 2022 Jun; 20(6):691-722. PubMed ID: 35714673
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR
Noordhoek I; Treuner K; Putter H; Zhang Y; Wong J; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; van de Velde CJH; Schnabel CA; Liefers GJ
Clin Cancer Res; 2021 Jan; 27(1):311-319. PubMed ID: 33109739
[TBL] [Abstract][Full Text] [Related]
14. Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory.
AlOmeir O; Patel N; Donyai P
Support Care Cancer; 2020 Nov; 28(11):5075-5084. PubMed ID: 32601852
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Li L; Chang B; Jiang X; Fan X; Li Y; Li T; Wu S; Zhang J; Kariminia S; Li Q
BMC Cancer; 2018 Oct; 18(1):977. PubMed ID: 30314452
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
